New Pfizer Arthritis Drug passes 2nd Clinical Trial
New Pfizer Arthritis Drug passes 2nd Clinical
Trial
Pfizer Inc announced on Friday that its new experimental drug for rheumatoid arthritis has met its main goals in a late-stage clinical trial. It's a promising development for the world's largest pharmaceutical as it looks to offset losses from products that are set to lose patent protection.
The drug in question, tofacitinib, is one of Pfizer's most important new drugs. The company has said the drug's safety profile is consistent with those seen in previous trials, and that no new safety concerns have been found. The trial provided evidence that tofacitinib reduces symptoms of rheumatoid arthritis by a statistically significant amount compared with placebo treatment at six months. The drug also improved physical function in patients at three months, and increased incidents of remission at six months.
Patients who took part in the trial exhibited moderate to sever symptoms and had not responded adequately to traditional therapies. The trial is the second of six late-stage trials and follow the results of the first, released in November. Results from the final four trials are expected to be released by the middle of 2011. One analyst said the drug could generate as much as $2 billion in annual slaes if it is eventually approved.
Pfizer Inc announced on Friday that its new experimental drug for rheumatoid arthritis has met its main goals in a late-stage clinical trial. It's a promising development for the world's largest pharmaceutical as it looks to offset losses from products that are set to lose patent protection.
The drug in question, tofacitinib, is one of Pfizer's most important new drugs. The company has said the drug's safety profile is consistent with those seen in previous trials, and that no new safety concerns have been found. The trial provided evidence that tofacitinib reduces symptoms of rheumatoid arthritis by a statistically significant amount compared with placebo treatment at six months. The drug also improved physical function in patients at three months, and increased incidents of remission at six months.
Patients who took part in the trial exhibited moderate to sever symptoms and had not responded adequately to traditional therapies. The trial is the second of six late-stage trials and follow the results of the first, released in November. Results from the final four trials are expected to be released by the middle of 2011. One analyst said the drug could generate as much as $2 billion in annual slaes if it is eventually approved.
Comments
Top Stories
Latest DT's
-
1 month ago by Geno -
1 month ago by dallaseste
-
2 months ago by Geno
-
2 months ago by Geno
-
2 months ago by Geno
-
2 months ago by Geno
-
2 months ago by Geno
-
2 months ago by Geno
-
2 months ago by dallaseste
Top Authors
Subscribe
Games
Alias
3 Foot Ninja 2
ALIAS 2
Air Dodge
Battle Tanks
Bomber Bob
Cable Capers
Gem Mania
Hacker
Hostile Skies
Mission Mars
Bowling
Samurai Warrior
The Pharoh's Tomb
Monkey Lander
Muay Thai
Action
Donkey Kong Banana Barrage
501 Dart Challenge
Rooftop Skater
Zelda
Donkey Kong
Xtreme Pinball
Tetris
Connect 4
Battleships
Frogger
Penguin Push
Online Video Poker
Spank The Monkey
Mob Pay Back
Dealer
Yeti Sports Seal Bounce
Hold Your Drink Steady
Solitaire
Canyon Glider
3D Sudoku
Metal Slug Rampage
Street Fighter II
Flashman
Disc Golf
Table Tennis
Ninja Air Combat
Celebrity Hitman Terrorist Alert
Spider Solitaire
Tubin
Presidential Knockout
Global Player
Ma Balls
Baseball
Beckham Fit
0 Comments
Click here to sign up now.